Skechers +13%, Reports Upbeat Earnings, Joins These Climbing Stocks
U.S. stocks were higher, with the Dow Jones jumping over 150 points on Friday.Shares of Skechers U.S.A., Inc. (NYSE:SKX) rose sharply during Friday's session after the company reported better-than-exp
BenzingaApr 26 10:45 ET
APEV, PACB and BILI Are Among Premarket Gainers
Seeking AlphaApr 26 08:24 ET
PacBio Moved to Neutral at JPMorgan After Guidance Cut
Seeking AlphaApr 22 08:50 ET
Express News | JP Morgan Downgrades Pacific Biosciences to Neutral
Moomoo 24/7Apr 22 08:20 ET
Express News | Pacific Biosciences of California Inc : JP Morgan Cuts to Neutral From Overweight: JP Morgan Cuts to Neutral From Overweight
Moomoo 24/7Apr 21 22:45 ET
Pacific Biosciences Is Maintained at Neutral by Goldman Sachs
Pacific Biosciences Is Maintained at Neutral by Goldman Sachs
Dow JonesApr 19 10:48 ET
Express News | Goldman Sachs Maintains Neutral on Pacific Biosciences, Lowers Price Target to $2.5
Moomoo 24/7Apr 19 10:38 ET
Pacific Biosciences Price Target Cut to $2.50/Share From $7.00 by Goldman Sachs
Pacific Biosciences Price Target Cut to $2.50/Share From $7.00 by Goldman Sachs
Dow JonesApr 18 10:43 ET
PacBio Cut to Neutral at Goldman Sachs After Guidance Cut
Seeking AlphaApr 18 08:15 ET
Pacific Biosciences Is Maintained at Sector Outperform by Scotiabank
Pacific Biosciences Is Maintained at Sector Outperform by Scotiabank
Dow JonesApr 18 07:32 ET
Express News | Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $8
Moomoo 24/7Apr 18 07:22 ET
Express News | Pacific Biosciences of California Inc : Stephens Cuts Target Price to $3.50 From $9
Moomoo 24/7Apr 18 01:26 ET
A Glimpse Into The Expert Outlook On Pacific Biosciences Through 4 Analysts
Across the recent three months, 4 analysts have shared their insights on Pacific Biosciences (NASDAQ:PACB), expressing a variety of opinions spanning from bullish to bearish.The table below summarizes
BenzingaApr 17 16:00 ET
PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays
Yahoo FinanceApr 17 13:00 ET
Pacific Biosciences Is Maintained at Buy by TD Cowen
Pacific Biosciences Is Maintained at Buy by TD Cowen
Dow JonesApr 17 11:19 ET
Express News | TD Cowen Maintains Buy on Pacific Biosciences, Lowers Price Target to $2.5
Moomoo 24/7Apr 17 11:09 ET
Pacific Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/17/2024 75.44% TD Cowen $12 → $2.5 Maintains Buy 04/10/2024 110.53% Barclays $8 → $3 Maintains Equal-We
BenzingaApr 17 11:05 ET
Express News | Pacific Biosciences of California Inc : Scotiabank Cuts Target Price to $8 From $15
Moomoo 24/7Apr 17 09:02 ET
Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket
Shares of INVO Bioscience, Inc. (NASDAQ:INVO) rose sharply in today's pre-market trading after reporting fourth-quarter results. The company said quarterly revenue surged 397% year-over-year to $1,38
BenzingaApr 17 06:18 ET
Express News | Pacific Biosciences of California Inc : TD Cowen Cuts Target Price to $2.5 From $12
Moomoo 24/7Apr 17 00:01 ET
No Data
No Data